Fresh Tracks Therapeutics Past Earnings Performance

Past criteria checks 0/6

Fresh Tracks Therapeutics's earnings have been declining at an average annual rate of -5.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 12.8% per year.

Key information

-5.8%

Earnings growth rate

100.8%

EPS growth rate

Biotechs Industry Growth	-14.6%
Revenue growth rate	-12.8%
Return on equity	-57.3%
Net Margin	-71.1%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Fresh Tracks Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:VCC Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	8	-6	11
30 Sep 23	10	-9	14
30 Jun 23	3	-17	11
31 Mar 23	7	-16	13
31 Dec 22	7	-21	14
30 Sep 22	5	-23	14
30 Jun 22	5	-30	14
31 Mar 22	0	-40	13
31 Dec 21	0	-39	12
30 Sep 21	0	-41	12
30 Jun 21	0	-32	12
31 Mar 21	1	-26	12
31 Dec 20	2	-21	12
30 Sep 20	2	-24	13
30 Jun 20	4	-25	14
31 Mar 20	5	-24	12
31 Dec 19	8	-14	12
30 Sep 19	10	-7	9
30 Jun 19	12	-6	6
31 Mar 19	9	-7	6
31 Dec 18	11	-15	6
31 Dec 17	8	-23	6

Quality Earnings: VCC is currently unprofitable.

Growing Profit Margin: VCC is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: VCC is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.

Accelerating Growth: Unable to compare VCC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).

Return on Equity

High ROE: VCC has a negative Return on Equity (-57.34%), as it is currently unprofitable.

Fresh Tracks Therapeutics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Third quarter 2022 earnings released: US$2.07 loss per share (vs US$7.15 loss in 3Q 2021)

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: US$0.01 loss per share (vs US$7.29 loss in 2Q 2021)

Recent updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Third quarter 2022 earnings released: US$2.07 loss per share (vs US$7.15 loss in 3Q 2021)

Insufficient new directors

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Second quarter 2022 earnings released: US$0.01 loss per share (vs US$7.29 loss in 2Q 2021)

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.15 loss in 1Q 2021)

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought €113k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Forecast to breakeven in 2025

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

CEO & Director recently bought €99k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Revenue misses expectations

Brickell Biotech, Inc. to Report Q4, 2020 Results on Mar 09, 2021

New 90-day high: €1.36

Brickell Biotech, Inc. Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (Ecclock®)

New 90-day high: €0.90

Brickell Biotech, Inc. Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

Brickell Biotech, Inc. Announces Management Changes

Third quarter 2020 earnings released: US$0.15 loss per share

Brickell Biotech, Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day high: €0.91

Brickell Biotech, Inc. Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis

New 90-day low - €0.65

New 90-day low - €0.67

First half earnings released

Brickell Biotech, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies